Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318097 · ClinicalTrials.gov registry record
Histamine Responsiveness in McCune-Albright Syndrome
A clinical trial of McCune Albright Syndrome, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT00318097 is a study of McCune Albright Syndrome that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 22 participants, below the 370-participant average among 3 other McCune Albright Syndrome trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00318097, a study of McCune Albright Syndrome, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
McCune-Albright syndrome (MAS) is a syndrome caused by a genetic mutation that causes a specific protein in the body called a G protein to be constantly active. Children with McCune-Albright syndrome classically have early puberty, areas of increased skin pigmentation, and bone lesions resulting from the constant activity of the specific protein involved. Histamines are known to play a role in allergies and related allergic problems. The effects of histamines are controlled by the same G protein that is overly active in McCune-Albright syndrome. Thus, one could predict that patients with McCune-Albright may be at high risk for allergic problems. To date, no studies have documented any form of histamine excess or allergic difficulties in patients with McCune-Albright syndrome. However, the investigators have made the observation that a high percentage of their patients with MAS exhibit a range of allergic symptoms, from mild symptoms, to severe, life-threatening symptoms. The purpose of this study is to demonstrate increased histamine response by using a histamine skin test in patients with MAS. If increased reactions to histamines can be documented in MAS patients when compared to controls, severe and potentially life threatening allergic reactions in children with MAS could be anticipated and avoided.
Conditions Studied
Study Locations (1)
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2004-08-01 |
| Est. Completion | 2007-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318097
The ClinicalTrials.gov registry entry for NCT00318097 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 370-participant average among 3 other McCune Albright Syndrome trials with a reported enrollment target (94% lower). The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with McCune Albright Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00318097 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00318097 about?
NCT00318097 is a clinical study titled "Histamine Responsiveness in McCune-Albright Syndrome". McCune-Albright syndrome (MAS) is a syndrome caused by a genetic mutation that causes a specific protein in the body called a G protein to be constantly active. Children with McCune-Albright syndrome classically have early puberty, areas of increased skin pigmentation, and bone lesions resulting fro...
What is the current status of trial NCT00318097?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2004-08-01. Estimated completion is 2007-08-01.
What conditions does trial NCT00318097 study?
This clinical trial studies the following conditions: McCune Albright Syndrome.
Who is sponsoring clinical trial NCT00318097?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00318097 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for McCune Albright Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry
RECRUITING
-
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
RECRUITING
-
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.